Black Rock Inc. Durect Corp Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.43 - $5.9 $5,645 - $77,467	-13,130 Reduced 0.45%	2,912,596 $1.68 Million
Q2 2022 Aug 12, 2022	SELL	$0.38 - $0.64 $4.13 Million - $6.95 Million	-10,863,859 Reduced 78.78%	2,925,726 $1.4 Million
Q1 2022 May 12, 2022	SELL	$0.55 - $0.98 $81,142 - $144,581	-147,532 Reduced 1.06%	13,789,585 $9.24 Million
Q4 2021 Feb 10, 2022	SELL	$0.9 - $1.31 $363,894 - $529,668	-404,327 Reduced 2.82%	13,937,117 $13.7 Million
Q3 2021 Nov 09, 2021	BUY	$1.21 - $1.61 $47,479 - $63,174	39,239 Added 0.27%	14,341,444 $18.4 Million
Q2 2021 Aug 11, 2021	BUY	$1.6 - $2.02 $22.9 Million - $28.9 Million	14,302,205 New	14,302,205 $23.3 Million

593K

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $223M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.